GSA Capital Partners LLP Has $304,000 Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

GSA Capital Partners LLP reduced its stake in Exelixis, Inc. (NASDAQ:EXEL) by 81.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,708 shares of the biotechnology company’s stock after selling 52,983 shares during the quarter. GSA Capital Partners LLP’s holdings in Exelixis were worth $304,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Farallon Capital Management LLC grew its holdings in Exelixis by 1.6% during the second quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock worth $608,993,000 after buying an additional 424,000 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Exelixis by 0.4% during the second quarter. Renaissance Technologies LLC now owns 15,163,066 shares of the biotechnology company’s stock valued at $340,714,000 after purchasing an additional 61,350 shares during the period. LSV Asset Management grew its holdings in Exelixis by 107.7% during the second quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company’s stock valued at $129,511,000 after purchasing an additional 2,989,021 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Exelixis by 7.3% in the second quarter. Dimensional Fund Advisors LP now owns 5,137,201 shares of the biotechnology company’s stock valued at $115,434,000 after purchasing an additional 349,837 shares in the last quarter. Finally, AQR Capital Management LLC grew its position in shares of Exelixis by 12.7% in the second quarter. AQR Capital Management LLC now owns 3,281,578 shares of the biotechnology company’s stock valued at $73,425,000 after purchasing an additional 370,199 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EXEL has been the subject of several recent research reports. Wells Fargo & Company lifted their price target on Exelixis from $32.00 to $36.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Truist Financial lifted their price objective on Exelixis from $33.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. UBS Group initiated coverage on Exelixis in a research note on Thursday, September 19th. They set a “neutral” rating and a $30.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $29.00 target price on shares of Exelixis in a report on Wednesday, September 18th. Finally, Piper Sandler upped their target price on Exelixis from $33.00 to $36.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and a consensus target price of $31.44.

Insider Buying and Selling at Exelixis

In other Exelixis news, EVP Jeffrey Hessekiel sold 20,000 shares of Exelixis stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $25.79, for a total value of $515,800.00. Following the transaction, the executive vice president now owns 630,325 shares in the company, valued at $16,256,081.75. The trade was a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Dana Aftab sold 1,162 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total value of $36,486.80. Following the sale, the executive vice president now owns 498,945 shares in the company, valued at $15,666,873. The trade was a 0.23 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 289,736 shares of company stock valued at $9,471,510 in the last ninety days. Corporate insiders own 2.85% of the company’s stock.

Exelixis Stock Performance

Shares of Exelixis stock opened at $35.61 on Friday. Exelixis, Inc. has a one year low of $19.20 and a one year high of $36.60. The stock has a market cap of $10.17 billion, a price-to-earnings ratio of 22.83, a price-to-earnings-growth ratio of 0.87 and a beta of 0.51. The stock has a 50 day moving average price of $29.90 and a 200-day moving average price of $25.57.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.36 by $0.04. The company had revenue of $539.50 million during the quarter, compared to analysts’ expectations of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. Exelixis’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.10 EPS. Sell-side analysts predict that Exelixis, Inc. will post 1.68 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.